Why the study?
DM and PAD share pathophysiological pathways, and emerging data on agents targeting these pathways along with the pleiotropic effects of novel glucose-lowering drugs warrant summary.
Answers are grounded in this paper and cite their sources.
This review highlights emerging medical and interventional approaches, including novel glucose-lowering drugs, for managing peripheral artery disease in patients with diabetes mellitus.
Diabetes mellitus (DM) and peripheral artery disease (PAD) are two clinical entities closely associated. They share many pathophysiological pathways such as inflammation, endothelial dysfunction, oxidative stress and pro-coagulative unbalance. Emerging data focusing on agents targeting these pathways may be promising. Moreover, due to the increased cardiovascular risk, there is a growing interest in cardiovascular and "pleiotropic" effects of novel glucose lowering drugs. This review summarizes the main clinical features of PAD in patients, the diagnostic process and current medical/interventional approaches, ranging from "classical treatment" to novel agents.
No takes yet. Share an insight, caveat, or question.
Demarchi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: